Anti-tuberculosis treatment strategies and drug development: challenges and priorities

VA Dartois, EJ Rubin - Nature Reviews Microbiology, 2022 - nature.com
treatment strategies and challenges. We review new technological advances in mycobacteriology,
their impact on TB drug discovery and development, … the development of curative drug

Strategies to improve drug development for sepsis

MP Fink, HS Warren - Nature reviews Drug discovery, 2014 - nature.com
treatment with the drug ameliorated the development of hypotension in rats that were
challenged with either LPS or purified LTA 96 . Interestingly, in these studies, pretreatment and post…

Strategies for modern biomarker and drug development in oncology

AD Smith, D Roda, TA Yap - Journal of Hematology & Oncology, 2014 - Springer
… that illustrate the importance of a rational approach to drug development. We will discuss
strategies … is essential to identifying the mechanism of resistance and a new treatment strategy. …

Current status and research strategies in tuberculosis drug development: miniperspective

LG Dover, GD Coxon - Journal of medicinal Chemistry, 2011 - ACS Publications
… with drug development and treatmenttreatment consists of an initial 2-month phase of
treatment with INH, RIF, PZA, and ethambutol (EMB) followed by a continuation phase of treatment

Clinical-pharmacological strategies to assess drug interaction potential during drug development

J Kuhlmann, W Mück - Drug safety, 2001 - Springer
… assessment of development potential; setting up a rational in vivo drug-drug interaction …
to drug interactions and may help to improve the quality of drug treatment and to save costs. …

Drug development and clinical trials—the path to an approved cancer drug

EH Rubin, DG Gilliland - Nature reviews Clinical oncology, 2012 - nature.com
strategies, … drug development that will help accelerate approval of drugs, and aim to provide
more-effective treatments alongside companion diagnostic tests to ensure the right treatment

The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development

FJ Martinez, JF Donohue, SI Rennard - The Lancet, 2011 - thelancet.com
… In the specific context of drug development, the US Food and Drug Administration (FDA)
will accept qualification of a biomarker in several specific contexts, including stratification of …

Model‐based drug development

RL Lalonde, KG Kowalski… - Clinical …, 2007 - Wiley Online Library
… Thus, we should view drug development as a model building … to inform our decision-making
and drug development strategy. … The treatment effect (Δ) of a drug relative to placebo or an …

Applying insights from biofilm biology to drug development—can a new approach be developed?

T Bjarnsholt, O Ciofu, S Molin, M Givskov… - Nature reviews Drug …, 2013 - nature.com
treatment of biofilm infections presents a considerable unmet clinical need. To date, there
are no drugs … , several approaches are in early-stage development. Here, we review current …

Orphan drug: Development trends and strategies

A Sharma, A Jacob, M Tandon… - Journal of Pharmacy and …, 2010 - journals.lww.com
… , treatment, monitoring, and patient support. Incentives for drug development provided by …
drugs. Although there may still be challenges ahead for the pharmaceutical industry, orphan …